


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>SUPPLEMENTAL          INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>140140.401C1</b>		APPLICATION NO. <b>10/782,024</b>	
				APPLICANTS <b>John G. Bauman et al.</b>			
				FILING DATE <b>February 18, 2004</b>			
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	AI						
	AJ						
	AK						
	AL						
<b>OTHER ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
DDC	AM	Bannenberg, G. et al., "Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration," <i>British Journal of Pharmacology</i> 143(1): 43-52, 2004.					
↓	AN	Fiorucci, S. et al., "A $\beta$ -oxidation-resistant lipoxin A <sub>4</sub> analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction," <i>Proc. Natl. Acad. Sci. USA</i> 101(44): 15736-15741, November 2, 2004.					
↓	AO	Guilford, W.J. et al., "Novel 3-Oxa Lipoxin A <sub>4</sub> Analogues with Enhanced Chemical and Metabolic Stability Have Anti-inflammatory Activity in Vivo," <i>Journal of Medicinal Chemistry</i> 47(8): 2157-2165, 2004.					
↓	AP	Guilford, W.J. et al., "Second-generation beta-oxidation resistant 3-oxa-lipoxin A <sub>4</sub> analogs," <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> 73: 245-250, 2005.					
EXAMINER  /Deborah Carr/				DATE CONSIDERED  04/28/2006			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							